NASDAQ:NKTX Nkarta (NKTX) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free NKTX Stock Alerts $6.82 -0.35 (-4.88%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$6.47▼$7.0050-Day Range$7.17▼$15.7152-Week Range$1.28▼$16.24Volume1.55 million shsAverage Volume1.87 million shsMarket Capitalization$337.02 millionP/E RatioN/ADividend YieldN/APrice Target$17.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Nkarta alerts: Email Address Nkarta MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside161.5% Upside$17.83 Price TargetShort InterestBearish11.27% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$20 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.34) to ($2.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.51 out of 5 starsMedical Sector401st out of 907 stocksPharmaceutical Preparations Industry176th out of 422 stocks 4.5 Analyst's Opinion Consensus RatingNkarta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNkarta has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.27% of the outstanding shares of Nkarta have been sold short.Short Interest Ratio / Days to CoverNkarta has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Nkarta has recently increased by 14.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNkarta does not currently pay a dividend.Dividend GrowthNkarta does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NKTX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Nkarta this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for NKTX on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Nkarta to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nkarta insiders have bought 40,128.50% more of their company's stock than they have sold. Specifically, they have bought $20,000,000.00 in company stock and sold $49,716.00 in company stock.Percentage Held by InsidersOnly 5.60% of the stock of Nkarta is held by insiders.Percentage Held by Institutions80.54% of the stock of Nkarta is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nkarta are expected to grow in the coming year, from ($2.34) to ($2.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nkarta is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nkarta is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNkarta has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Nkarta Stock (NASDAQ:NKTX)Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More NKTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKTX Stock News HeadlinesMarch 30, 2024 | insidertrades.comSimeon George Purchases 2,000,000 Shares of Nkarta, Inc. (NASDAQ:NKTX) StockApril 18, 2024 | finance.yahoo.comNkarta, Inc. (NKTX) Interactive Stock Chart - Yahoo FinanceApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)April 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Arcutis Biotherapeutics (ARQT)April 8, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 5, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 5, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 3, 2024 | globenewswire.comNkarta to Participate in Upcoming Investor ConferencesMarch 31, 2024 | 247wallst.comHuge Insider Buying From Buffett, an NFL Team Owner, a New CEOMarch 27, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)March 27, 2024 | msn.comPromising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-HeartedMarch 26, 2024 | sg.finance.yahoo.comNkarta, Inc. (NKTX) interactive stock chart – Yahoo FinanceMarch 25, 2024 | seekingalpha.comNkarta: NK Cell Therapy Advancement On Two FrontsMarch 25, 2024 | msn.comNkarta announces pricing of stock offering to raise $240.1MMarch 25, 2024 | markets.businessinsider.comNkarta Prices $240 Mln Offering; Stock Up Over 16%March 25, 2024 | globenewswire.comNkarta Announces Pricing of $240 Million Underwritten OfferingMarch 25, 2024 | markets.businessinsider.comNkarta’s Strategic Pivot to CAR-NK Therapies for Autoimmune Diseases Prompts Buy RatingMarch 23, 2024 | finance.yahoo.comNkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline RealignmentMarch 22, 2024 | finanznachrichten.deNkarta, Inc.: Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsMarch 22, 2024 | markets.businessinsider.comBuy Rating for Nkarta: Promising Future for NKX019 in Autoimmune Disease TreatmentMarch 22, 2024 | markets.businessinsider.comNkarta’s Strategic Focus and Financial Strength Underpin Buy RatingMarch 22, 2024 | msn.comThese Analysts Revise Their Forecasts On Nkarta After Q4 ResultsMarch 21, 2024 | investorplace.comNKTX Stock Earnings: Nkarta Beats EPS for Q4 2023March 21, 2024 | globenewswire.comNkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsMarch 19, 2024 | markets.businessinsider.comInnovative NK-Cell Therapy: A Buy Rating for Nkarta’s Groundbreaking Approach to Autoimmune DiseasesSee More Headlines Receive NKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NKTX CUSIPN/A CIK1787400 Webwww.nkartatx.com Phone925-407-1049FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$17.83 High Stock Price Target$25.00 Low Stock Price Target$15.00 Potential Upside/Downside+161.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.06% Return on Assets-28.11% Debt Debt-to-Equity RatioN/A Current Ratio10.85 Quick Ratio10.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book1.23Miscellaneous Outstanding Shares49,416,000Free Float46,649,000Market Cap$337.02 million OptionableOptionable Beta0.70 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Paul J. Hastings (Age 64)CEO, President & Director Comp: $938.41kDr. Alicia J. Hager (Age 54)Chief Legal Officer & Corporate Secretary Comp: $590.94kMs. Alyssa Levin C.A. (Age 39)CPA, Chief Financial & Business Officer and Principal Accounting Officer Dr. Ralph Brandenberger Ph.D. (Age 55)Chief Technical Officer Dr. James Trager Ph.D. (Age 61)Chief Scientific Officer Mr. Greg MannVice President of Public Affairs and Investor RelationsDr. David R. Shook M.D. (Age 46)Chief Medical Officer More ExecutivesKey CompetitorsAlto NeuroscienceNYSE:ANRONature's Sunshine ProductsNASDAQ:NATRPepGenNASDAQ:PEPGRevance TherapeuticsNASDAQ:RVNCHarrow HealthNASDAQ:HROWView All CompetitorsInsiders & InstitutionsSimplicity Wealth LLCBought 15,827 shares on 4/24/2024Ownership: 0.032%Denali Advisors LLCBought 26,500 shares on 4/19/2024Ownership: 0.054%Wasatch Advisors LPSold 931,207 shares on 4/18/2024Ownership: 2.364%Simeon GeorgeBought 2,000,000 shares on 3/27/2024Total: $20 M ($10.00/share)Leo Wealth LLCBought 54,848 shares on 3/14/2024Ownership: 0.112%View All Insider TransactionsView All Institutional Transactions NKTX Stock Analysis - Frequently Asked Questions Should I buy or sell Nkarta stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NKTX shares. View NKTX analyst ratings or view top-rated stocks. What is Nkarta's stock price target for 2024? 5 Wall Street research analysts have issued 1 year price targets for Nkarta's stock. Their NKTX share price targets range from $15.00 to $25.00. On average, they predict the company's share price to reach $17.83 in the next year. This suggests a possible upside of 161.5% from the stock's current price. View analysts price targets for NKTX or view top-rated stocks among Wall Street analysts. How have NKTX shares performed in 2024? Nkarta's stock was trading at $6.60 at the start of the year. Since then, NKTX stock has increased by 3.3% and is now trading at $6.82. View the best growth stocks for 2024 here. When is Nkarta's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our NKTX earnings forecast. How were Nkarta's earnings last quarter? Nkarta, Inc. (NASDAQ:NKTX) issued its earnings results on Thursday, March, 21st. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.05. What other stocks do shareholders of Nkarta own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG). When did Nkarta IPO? Nkarta (NKTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities acted as the underwriters for the IPO. Who are Nkarta's major shareholders? Nkarta's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (2.36%), Denali Advisors LLC (0.05%) and Simplicity Wealth LLC (0.03%). Insiders that own company stock include David Shook, Dawn N Edwards, James Trager, Kanya Rajangam, Nadir Mahmood, Paul J Hastings, Paul J Hastings, Ra Capital Management, LP, Ralph Brandenberger and Simeon George. View institutional ownership trends. How do I buy shares of Nkarta? Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NKTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyYour Money is Not SafeAmerican AlternativeJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsKeep Your Eyes on This Power-Mad PoliticianAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
